The drugstore box used to be one of the easiest stories in net lease.
A national pharmacy tenant. A long lease. A hard-corner site. Investment-grade credit. A familiar blue or red sign. For years, that combination gave 1031 buyers and private investors a simple mental shortcut: pharmacy real estate was essential retail with bond-like rent.
That shortcut no longer works.
The property type is still useful. Some pharmacy sites remain among the best-located retail boxes in their trade areas. CVS still carries investment-grade credit. Many former Rite Aid and Walgreens locations sit on signalized corners with drive-thrus, strong traffic counts, and expensive replacement land. But the sector has split into three different underwriting stories: CVS as the remaining investment-grade pharmacy credit, Walgreens as a private, non-investment-grade restructuring case, and Rite Aid as a former tenant whose real estate must now be valued on reuse and replacement economics.
That split is now visible in cap rates. In InvestmentGrade.com’s Q1 2026 net lease data, CVS moved to roughly 6.80%, Walgreens moved to roughly 8.10%, and the drug store sector average moved to roughly 7.85%. The spread between CVS and Walgreens is not a rounding error. It is the market saying that pharmacy NNN properties cannot be priced by sector label anymore.
For a 1031 buyer, the key question is not "what do pharmacy cap rates average?" The better question is: what part of the pharmacy risk stack am I actually buying?
The old pharmacy cap-rate story broke for a reason
The pharmacy sector is being repriced because the tenant model changed.
The front end of the store lost traffic to discounters, Amazon, grocery, dollar stores, and online convenience. Pharmacy reimbursement pressure reduced margin flexibility. Labor and theft pressure hit store-level economics. Large operators discovered that their dense store networks were built for a different era of retail behavior. The result has been a multi-year rationalization of locations, not a one-quarter wobble.
LightBox described the shift clearly in its 2025 pharmacy downsizing analysis: Walgreens and CVS are reshaping their footprints, Walgreens planned roughly 500 closures in 2025 as part of a broader 1,200-store program, and CVS had closed more than 1,000 locations since 2022 with another roughly 270 planned in 2025. Rite Aid added a more severe version of the same lesson. After a second Chapter 11 filing in May 2025, the company moved into a wind-down and asset-sale process, leaving former Rite Aid boxes to trade on real estate reuse rather than going-concern tenant credit.
That is why generic pharmacy cap-rate comparisons are dangerous. A CVS with a parent guarantee and 15 years of lease term, a Walgreens under private ownership with store-closure exposure, and a former Rite Aid box with no operating tenant are three different investments. They may all look like pharmacy real estate from the curb. They do not have the same rent durability.
CVS: investment-grade credit, but not risk-free pricing
CVS remains the cleanest credit story among the major pharmacy tenants.
The company is still investment grade, with public ratings around the BBB/Baa3 level. CVS leases are corporate rather than franchisee-backed, which means the buyer is generally underwriting CVS Health as the rent-paying credit rather than a local operator. That matters. In a sector where the brand on the building can obscure the actual obligor, CVS usually gives buyers a clearer credit package.
But a CVS is not automatically a core asset just because the tenant is rated.
CVS is also rationalizing its store base. It has been closing locations as part of a strategic footprint reset, even while maintaining broad national pharmacy access. That means site selection matters more than it did when the sector was priced as a near-uniform essential-retail sleeve. Investors should separate a durable CVS location from an older, redundant store in an over-stored trade area.
In cap-rate terms, the Q1 2026 pharmacy data suggest CVS assets are pricing around the high-6% range, with better sites and longer leases tighter, and weaker or shorter-term locations wider. That is a substantial premium to where high-quality pharmacy properties traded in the low-rate era, but it does not mean every CVS is cheap. It means the market is demanding a wider yield for healthcare-retail transition risk, reimbursement pressure, and store-rationalization uncertainty.
A good CVS NNN buyer should underwrite at least five items before accepting the cap rate:
- Is the lease guaranteed by CVS Health, and are there any entity-level complications?
- How many years remain before the first real renewal decision?
- Does the rent match replacement-market economics if CVS leaves?
- Is the site still a dominant pharmacy location, or is it one of several redundant stores in the same trade area?
- Can the property be reused by another tenant without a major value reset?
The answer to those questions matters more than the published sector average.
Walgreens: the cap-rate premium is a credit signal
Walgreens is the more difficult underwriting case.
For years, Walgreens properties traded with the comfort of a recognizable national tenant, long lease terms, and strong corner real estate. That comfort has thinned. Walgreens went private under Sycamore Partners in 2025, public ratings transparency disappeared, and the company entered a restructuring period with significant store closures and elevated leverage concerns.
InvestmentGrade.com’s Walgreens tenant profile treats the company as below the investment-grade threshold after privatization, with former public ratings in non-investment-grade territory before withdrawal. The important point for NNN buyers is simple: a Walgreens cap rate should no longer be interpreted the way investors interpreted Walgreens cap rates a decade ago.
A Walgreens at roughly 8.10% in Q1 2026 is not merely "more yield" than a CVS. It is a market-priced warning label. Buyers are being paid for less credit transparency, private-equity restructuring risk, store-closure exposure, and uncertainty around the long-term retail pharmacy model.
That does not mean every Walgreens property is bad real estate. Some Walgreens boxes are excellent real estate. Many occupy large, high-visibility hard-corner parcels with drive-thrus, parking, and strong access. Those features can support reuse if the tenant leaves. But the buyer must decide whether the investment thesis is tenant credit, dark-box reuse, or some blend of both.
A Walgreens with 18 years of lease term on a dominant corner in a wealthy suburb is not the same asset as a Walgreens with five years remaining in a declining trade area with duplicate nearby pharmacy coverage. The former might deserve a tighter cap rate because the lease term and site quality protect the basis. The latter might deserve a much wider yield because the cap rate is only compensating the buyer until the real estate has to stand on its own.
The underwriting question is not "is Walgreens safe?" That is too blunt. The right question is: if Walgreens stopped paying rent or rejected the location in a restructuring, what would the property be worth and how long would it take to restore income?
Rite Aid: no longer a tenant-credit trade
Rite Aid is the sector’s cautionary tale.
After its second bankruptcy in 2025 and subsequent wind-down, Rite Aid ceased to be a normal NNN tenant-credit investment. Properties marketed with Rite Aid history are no longer priced primarily by Rite Aid credit. They are former pharmacy boxes, assigned leases, rejected leases, fee-owned dispositions, or redevelopment opportunities.
That distinction is critical because a legacy Rite Aid cap rate can be misleading. If the lease has been rejected, there is no lease yield to capitalize. If the lease was assigned to another operator, the buyer must underwrite the new tenant and the new lease terms. If the building is vacant, the buyer is underwriting alternative use, carrying cost, tenant-improvement capital, leasing downtime, and the probability of backfilling the box.
Former Rite Aid sites can still have value. Some are on strong corners in dense neighborhoods. Some can be backfilled by grocers, medical users, discount retailers, urgent care, dollar stores, government users, or specialty retail. But that is not bond-like NNN income. It is real estate execution.
For 1031 buyers seeking passive replacement income, former Rite Aid real estate usually belongs in the "only with specialist conviction" bucket. A buyer who needs clean income, lender certainty, and low management burden should be very careful. A buyer with redevelopment experience, local leasing knowledge, and a tolerance for downtime may see opportunity. Those are not the same investor.
Why the spread between CVS and Walgreens matters
The CVS-Walgreens spread is one of the cleanest signals in the pharmacy market.
In the Q1 2026 data set, CVS around 6.80% and Walgreens around 8.10% implies a spread of about 130 basis points. That spread exists inside the same broad property category, often with similar building prototypes, similar corner locations, and similar investor memories. The market is not paying 130 basis points for aesthetics. It is paying for credit quality, transparency, closure probability, and exit liquidity.
This matters because many private buyers still compare pharmacy deals as if the tenants are close substitutes. They are not.
A lower cap CVS may produce a better risk-adjusted outcome than a higher cap Walgreens if the CVS lease is more financeable, more liquid at resale, and less exposed to near-term restructuring. Conversely, a Walgreens at a wider cap rate may be attractive if the lease term is long, the site is exceptional, rent is below market, and the buyer is comfortable underwriting the private-credit risk. The point is not that one tenant always wins. The point is that the cap rate must be read through the lease and credit stack.
A 1031 buyer who only sees yield will gravitate toward the 8% handle. A disciplined buyer asks why the market is offering that yield and whether the premium is enough.
Lease term can hide the problem or reveal it
Pharmacy leases are often long, but lease term alone can create false comfort.
A 20-year lease with a weakening tenant can feel secure because the rent schedule is long. But if the tenant’s store base is being rationalized, the lease term only matters if the tenant wants the location, needs the location, or has the balance sheet and legal incentive to keep paying for it. In a bankruptcy or restructuring, leases can be rejected. In a store-closure program, landlords may face renewal pressure, buyout discussions, dark stores, or reassignment risk.
That is why buyers should separate legal lease term from economic lease durability.
Legal lease term asks: how long does the lease say the tenant is obligated?
Economic lease durability asks: is this store profitable, strategically necessary, and worth preserving from the tenant’s perspective?
Those are different questions. The second question is harder to answer, but it is where the underwriting work lives.
Replacement rent is the real downside test
The most important pharmacy NNN downside test is replacement rent.
If CVS or Walgreens leaves, can another tenant pay the same rent for that box? If not, the cap rate was partly capitalizing rent above market. The investor may collect strong income during the lease term, then face a sharp value reset at rollover.
This is especially important for older pharmacy leases that were signed during aggressive expansion years. Some stores sit on excellent land but carry rents that are difficult for the next user to justify. Others have rents closer to market and can be reused more easily. The difference determines whether the property has true residual value.
A practical underwriting framework:
- Estimate current rent per square foot.
- Compare it with realistic replacement tenants in the trade area.
- Estimate downtime, tenant improvements, leasing commissions, and free rent.
- Revalue the property at stabilized replacement NOI.
- Compare that dark-value case with the purchase price.
If the downside value is too far below the acquisition basis, the buyer is not buying a conservative NNN asset. The buyer is buying a high-current-yield lease with a residual-value cliff.
What should a 1031 buyer do with pharmacy NNN today?
Pharmacy NNN is not dead. It is no longer lazy.
CVS can still fit a 1031 replacement strategy when the buyer wants investment-grade tenant credit, corporate lease exposure, and a healthcare-adjacent retail use. Walgreens can still make sense for yield-oriented buyers who understand the restructuring risk and can underwrite the underlying corner. Former Rite Aid real estate can create opportunity for specialists, but it should not be mistaken for passive credit income.
The cleanest way to screen the sector is to divide pharmacy properties into four buckets:
Core income: investment-grade CVS, long lease term, parent guarantee, strong corner, realistic replacement rent.
Credit-plus-real-estate: Walgreens or other pharmacy exposure where the site is strong enough to justify the risk premium.
Rollover-risk income: short lease term or questionable store economics where the going-in yield is attractive but the exit depends on renewal.
Reuse or redevelopment: former Rite Aid or dark pharmacy boxes where value depends on backfill, entitlement, or local-market execution.
Those buckets are more useful than a single drugstore cap-rate average.
The underwriting bottom line
Pharmacy NNN used to trade on a simple assumption: national pharmacy chains were essential, durable, and easy to finance. The sector now requires a more disciplined reading.
CVS is the remaining investment-grade anchor, but still needs store-level and rent-level review. Walgreens offers wider yield because the market is pricing private-credit and closure risk. Rite Aid is no longer a tenant-credit story. It is a real estate reuse story.
For 1031 buyers, that creates both risk and opportunity. The risk is buying yesterday’s pharmacy narrative at today’s cap rate without understanding what changed. The opportunity is using the reset to buy strong real estate at a fairer yield, while avoiding boxes where the lease income is stronger than the real estate underneath it.
If you are comparing pharmacy NNN replacement properties, InvestmentGrade.com can review the tenant credit, lease structure, rent level, and residual real estate risk before you identify or close. The cap rate is the starting point. The underwriting answer is in the spread between the tenant, the lease, and the site.
Sources and further reading: InvestmentGrade.com’s NNN Cap Rates 2026 market data, CVS Credit Rating and NNN Cap Rate, Walgreens Credit Rating and NNN Cap Rate, Rite Aid Credit Rating and NNN Status, and LightBox analysis of pharmacy downsizing in 2025.
